Strides is reportedly one of the few approved manufacturers in India of this product – the generic equivalent of Roche’s Tamiflu.
At present limited stocks oseltamivir are available but the company is gearing capacities to produce in excess of two million doses per month starting June 2009, said Strides Arcolab.
Aloka Sengupta, president of business development for India operations at Strides Arcolab, said: “We are particularly well equipped to handle such emergencies as we specialize in manufacture and supply of products that are used to treat similar disease epidemics.”